<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, May 30, 2018 (HealthDay News) — BRCA1\/BRCA2<\/i> germline mutation carriers with pancreatic ductal adenocarcinoma (PDAC) have worse survival after resection, according to a study published in the April issue of the Journal of the American College of Surgeons<\/i>.<\/p>\n
Alex B. Blair, M.D., from Johns Hopkins Medical Institutions in Baltimore, and colleagues performed targeted next-generation sequencing to identify BRCA1\/BRCA2<\/i> germline mutations in resected sporadic PDAC cases from 2000 to 2015. Germline BRCA<\/i> mutation carriers (four patients with BRCA1<\/i> and 18 with BRCA2<\/i>) were matched to those with BRCA1\/BRCA2<\/i> wild-type genes (105 patients). Overall survival (OS) and disease-free survival (DFS) were compared between the cohorts.<\/p>\n
The researchers found that, compared with matched wild-type controls, the BRCA1\/BRCA2<\/i> mutations correlated with significantly inferior median OS (20.2 versus 27.8 months) and DFS (8.4 versus 16.7 months). There were significant independent correlations for BRCA1\/BRCA2<\/i> mutation, positive margin status, and lack of adjuvant therapy with worse survival in multivariable analysis (hazard ratios, 2.10, 1.72, and 2.38, respectively). Having had platinum-based adjuvant chemotherapy correlated with significantly better survival than alternative chemotherapy or no adjuvant chemotherapy within the BRCA1\/BRCA2<\/i> mutated group (31.0 versus 17.8 and 9.3 months, respectively).<\/p>\n
“Carriers of BRCA1\/BRCA2<\/i> mutation with sporadic PDAC had a worse survival after pancreatectomy than their BRCA<\/i> wild-type counterparts,” the authors write. “However, platinum-based chemotherapy regimens were associated with markedly improved survival in patients with BRCA1\/BRCA2<\/i> mutations, with survival differences no longer appreciated with wild-type patients.”<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n